A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
19
05
2021
accepted:
04
10
2021
revised:
07
09
2021
pubmed:
28
10
2021
medline:
11
1
2022
entrez:
27
10
2021
Statut:
ppublish
Résumé
Identifying families with an underlying inherited cancer predisposition is a major goal of cancer prevention efforts. Mendelian risk models have been developed to better predict the risk associated with a pathogenic variant of developing breast/ovarian cancer (with BRCAPRO) and the risk of developing pancreatic cancer (PANCPRO). Given that pathogenic variants involving BRCA2 and BRCA1 predispose to all three of these cancers, we developed a joint risk model to capture shared susceptibility. We expanded the existing framework for PANCPRO and BRCAPRO to jointly model risk of pancreatic, breast, and ovarian cancer and validated this new model, BRCAPANCPRO on three data sets each reflecting the common target populations. BRCAPANCPRO outperformed the prior BRCAPRO and PANCPRO models and yielded good discrimination for differentiating BRCA1 and BRCA2 carriers from non-carriers (AUCs 0.79, 95% CI: 0.73-0.84 and 0.70, 95% CI: 0.60-0.80) in families seen in high-risk clinics and pancreatic cancer family registries, respectively. In addition, BRCAPANCPRO was reasonably well calibrated for predicting future risk of pancreatic cancer (observed-to-expected (O/E) ratio = 0.81 [0.69, 0.94]). The BRCAPANCPRO model provides improved risk assessment over our previous risk models, particularly for pedigrees with a co-occurrence of pancreatic cancer and breast and/or ovarian cancer.
Identifiants
pubmed: 34703010
doi: 10.1038/s41416-021-01580-x
pii: 10.1038/s41416-021-01580-x
pmc: PMC8651643
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1712-1717Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : U01CA247283
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : P30CA006516
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : P30CA006973
Organisme : NCI NIH HHS
ID : R01 CA097075
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132829
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : NCI P50 CA62924
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145–58.
doi: 10.1086/301670
Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89:227–38.
doi: 10.1093/jnci/89.3.227
Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2007;25:1417–22.
doi: 10.1200/JCO.2006.09.2452
Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296:1479–87.
doi: 10.1001/jama.296.12.1479
Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol. 2002;23:133–49.
doi: 10.1002/gepi.1102
Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, et al. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007;147:441–50.
doi: 10.7326/0003-4819-147-7-200710020-00002
Leonardi G, Marchi S, Falconi M, Zerbi A, Ussia V, de Bortoli N, et al. “PancPro” as a tool for selecting families eligible for pancreatic cancer screening: an Italian study of incident cases. Dig Liver Dis. 2012;44:585–8.
doi: 10.1016/j.dld.2011.12.019
Kurian AW, Gong GD, John EM, Miron A, Felberg A, Phipps AI, et al. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomark Prev. 2009;18:1084–91.
doi: 10.1158/1055-9965.EPI-08-1090
Chen S, Wang W, Broman KW, Katki HA, Parmigiani G. BayesMendel: and R environment for Mendelian risk prediction. Stat Appl Genet Mol Biol. 2004;3:Article21.
SEER. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2018), National Cancer Institute, DCCPS, Surveillance Research Program, released December 2019. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch; 2019.
Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319:2401–9.
doi: 10.1001/jama.2018.6228
Mocci E, Milne RL, Mendez-Villamil EY, Hopper JL, John EM, Andrulis IL, et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomark Prev. 2013;22:803–11.
doi: 10.1158/1055-9965.EPI-12-0195
Petersen GM, de Andrade M, Goggins M, Hruban RH, Bondy M, Korczak JF, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomark Prev. 2006;15:704–10.
doi: 10.1158/1055-9965.EPI-05-0734
Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17:569–77.
doi: 10.1038/gim.2014.153
Brune KA, Lau B, Palmisano E, Canto M, Goggins MG, Hruban RH, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102:119–26.
doi: 10.1093/jnci/djp466
Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634–8.
doi: 10.1158/0008-5472.CAN-03-3823
Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.
doi: 10.1093/jnci/81.24.1879
Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98:1457–66.
doi: 10.1038/sj.bjc.6604305
Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, et al. CanRisk tool-a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomark Prev. 2021;30:469–73.
doi: 10.1158/1055-9965.EPI-20-1319
Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35:3382–90.
Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019;21:213–23.
doi: 10.1038/s41436-018-0009-5
Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33:3124–9.
doi: 10.1200/JCO.2014.59.7401
Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009;137:1183–6.
doi: 10.1053/j.gastro.2009.06.055
Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324:217.
doi: 10.1126/science.1171202
Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, et al. Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, Hispanic, and other minority families in the United States. J Clin Oncol. 2009;27:1184–90.
doi: 10.1200/JCO.2008.17.5869
Takai E, Yachida S, Shimizu K, Furuse J, Kubo E, Ohmoto A, et al. Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget. 2016;7:74227–35.
doi: 10.18632/oncotarget.12490
Chen S, Blackford AL, Parmigiani G. Tailoring BRCAPRO to Asian-Americans. J Clin Oncol. 2009;27:642–3. Author reply 643–4.
doi: 10.1200/JCO.2008.20.6896
Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2:41–46.
doi: 10.1158/2159-8290.CD-11-0194
Tai YC, Chen S, Parmigiani G, Klein AP. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008;10:401.
doi: 10.1186/bcr1866
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27.
doi: 10.1056/NEJMoa1903387
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.
doi: 10.1126/science.aan6733
Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140:199–203.
doi: 10.1016/j.ygyno.2015.12.020
Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C, et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37:153–64.
doi: 10.1200/JCO.18.01489
Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020;18:380–91.
doi: 10.6004/jnccn.2020.0017
Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016;6:166–75.
doi: 10.1158/2159-8290.CD-15-0402